
TREATMENTS
Exploring new frontiers for the treatment of Diabetes
TREATMENTS
Exploring new frontiers for the treatment of Diabetes
17+ Years of using patented and proven stem cell treatment for Diabetes
Diabetes is an autoimmune disease in which the body cannot effectively regulate and use glucose (sugar) in the blood. This condition develops when the body either can’t prepare insulin or can’t respond to the insulin. If not controlled, diabetes can lead to blindness, kidney failure, heart diseases and stroke.
Conventionally, Type 1 diabetes patients are given insulin to help process sugar. Diabetes in Type 2 can sometimes be controlled with diet and exercise with other steroid-based medications to deal with complications from the disease. Stem cell treatments are designed after thoroughly assessing a patient’s clinical condition. Once the treatment protocol is initiated, progress is monitored at regular intervals using the Nutech Functional System for finer assessment and advanced alignment of the treatment protocol.
Stem cells administered in the body through veins or lumbar puncture are used to repopulate the damaged parts of the pancreas to initiate secretion of new immune cells. Nutech MediWorld’s Stem Cell Treatment is designed to improve insulin dependence, fasting plasma glucose and C-peptide levels, with tight glycemic control and correction of glycated hemoglobin levels among patients with Diabetes.
We assess the patients’ clinical condition to evaluate if he/she is eligible for the procedure of Stem Cell Treatment for Diabetes.
We also conduct an additional round of thorough assessment using our NFS (Nutech Functional System) protocols whereby condition-based sets of parameters have been pre-devised for a finer assessment of the patient’s condition (and progress).
After evaluating the specific patient’s condition, a unique/bespoke treatment protocol is decided. This protocol is based on our proprietary stem cell platform, Reostem®.
The patient’s progress is monitored on a weekly basis to further optimize treatment protocols depending on the patient’s response.
At the end of the treatment, a complete assessment is done to track progress from when the patient came into where he/she has reached now. If required, a follow-up protocol is recommended.
At Nutech MediWorld, we follow an evidence-based, non-invasive, multi-disciplinary approach using Stem Cell Treatment & supporting therapies to improve the condition and overall quality of life for Diabetes patients. Each treatment protocol comprises of the use of our patented technology, customized to suit the condition of the individual patient.
At Nutech Mediworld, we follow an evidence-based, non-invasive, multi-disciplinary approach using Stem Cell Treatment & supporting therapies to improve the condition and overall quality of life for Cerebral Palsy Patients. Each treatment protocol comprises of the use of our patented technology, customized to suit the condition of the individual patient
We assess the patients’ clinical condition to evaluate if he/she is eligible for the procedure of Stem Cell Treatment for Diabetes.
We also conduct an additional round of thorough assessment using our NFS (Nutech Functional System) protocols whereby condition-based sets of parameters have been pre-devised for a finer assessment of the patient’s condition (and progress).
After evaluating the specific patient’s condition, a unique/bespoke treatment protocol is decided. This protocol is based on our proprietary stem cell platform, Reostem ®.
The patient’s progress is monitored on a weekly basis to further optimize treatment protocols depending on the patient’s response.
At the end of the treatment, a complete assessment is done to track progress from when the patient came into where he/she has reached now. If required, a follow-up protocol is recommended
We use SCT-N® and SCT-NX® products, based on a proprietary stem cell platform, ReoStem®. ReoStem® is a unique, replicable, clinical-stage technology platform for the generation of allogenic stem cells.
Nutech MediWorld’s regenerative medicine products are universally applicable: they do not require tissue-matching or the co-administration of immunosuppressive drugs.
There is absolutely no evidence of teratoma generation or tumorigenesis associated with SCT-N® or SCT-NX® use in over 17 years of clinical practice across thousands of patients.
Unique cell culture methodology allows scalability of cell expansion and production.